These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 19781875)

  • 21. Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone.
    Hellgren M; Conard J; Norris L; Kluft C
    Maturitas; 2009 Mar; 62(3):287-93. PubMed ID: 19268506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women.
    Nugent AG; Leung KC; Sullivan D; Reutens AT; Ho KK
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):690-8. PubMed ID: 14974909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of severe primary and secondary dysmenorrhea with a retrosteroid].
    Bayer R
    Wien Med Wochenschr; 1971 Sep; 121(36):618-24. PubMed ID: 5110842
    [No Abstract]   [Full Text] [Related]  

  • 24. Dydrogesterone as an Option in the Medical Treatment of Endometriosis: A Brief Comment.
    Carvalho BR
    Rev Bras Ginecol Obstet; 2022 Aug; 44(8):802-803. PubMed ID: 35839819
    [No Abstract]   [Full Text] [Related]  

  • 25. Luteal support: progestogens for pregnancy protection.
    Daya S
    Maturitas; 2009 Dec; 65 Suppl 1():S29-34. PubMed ID: 19913373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New data about preeclampsia: some possibilities of prevention.
    Schindler AE
    Gynecol Endocrinol; 2018 Aug; 34(8):636-637. PubMed ID: 29508649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of threatened abortion with dydrogesterone].
    Ehrenskjöld ML; Bondo B; Weile F
    Ugeskr Laeger; 1967 Dec; 129(50):1678-9. PubMed ID: 5889245
    [No Abstract]   [Full Text] [Related]  

  • 28. Oral dydrogesterone treatment during the first trimester of pregnancy: the prevention of miscarriage study (PROMIS). A double-blind, prospectively randomized, placebo-controlled, parallel group trial.
    Walch K; Hefler L; Nagele F
    J Matern Fetal Neonatal Med; 2005 Oct; 18(4):265-9. PubMed ID: 16318978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dydrogesterone use during pregnancy: overview of birth defects reported since 1977.
    Queisser-Luft A
    Early Hum Dev; 2009 Jun; 85(6):375-7. PubMed ID: 19193503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Apropos of the use of dydrogesterone in gynecology and obstetrics; clinical experience].
    Gellé P; Schaeffer P
    Bull Fed Soc Gynecol Obstet Lang Fr; 1965; 17(4):369-70. PubMed ID: 5858369
    [No Abstract]   [Full Text] [Related]  

  • 31. Duphaston depot, a new long-acting progestogen.
    Schellen AM
    Bull Soc R Belge Gynecol Obstet; 1969; 39(4):327-31. PubMed ID: 5408050
    [No Abstract]   [Full Text] [Related]  

  • 32. Indications for therapy with progestational agents.
    Darragh A
    Bull Schweiz Akad Med Wiss; 1970 Oct; 25(4-6):541-4. PubMed ID: 5534331
    [No Abstract]   [Full Text] [Related]  

  • 33. Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone.
    Patki A; Pawar VC
    Gynecol Endocrinol; 2007 Oct; 23 Suppl 1():68-72. PubMed ID: 17943542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Induction of mensruation with retrosteroid Ro 4-8347 in amenorrhea and its suitability as a pregnancy test in negative reactions (Retroid, Hoffman-La Roche)].
    Bayer R
    Wien Klin Wochenschr; 1971 May; 83(21):384-7. PubMed ID: 5094993
    [No Abstract]   [Full Text] [Related]  

  • 35. [Experiences with 6-dehydro-retroprogesterone int the treatment of placental insufficiency].
    Mistò A
    Ann Ostet Ginecol Med Perinat; 1967 Feb; 89(2):102-12. PubMed ID: 5601176
    [No Abstract]   [Full Text] [Related]  

  • 36. [Effect of the gestagen RO 4-8347].
    Lutziger H
    Gynaecologia; 1969; 167(5):444-9. PubMed ID: 5802924
    [No Abstract]   [Full Text] [Related]  

  • 37. Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone.
    Norris LA; Brosnan J; Bonnar J; Conard J; Kluft C; Hellgren M
    Thromb Haemost; 2008 Aug; 100(2):253-60. PubMed ID: 18690345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of dydrogesterone on abortion induced by intra-amniotic hypertonic saline.
    Fuchs F; Klopper A
    J Obstet Gynaecol Br Commonw; 1969 May; 76(5):462-3. PubMed ID: 5769206
    [No Abstract]   [Full Text] [Related]  

  • 39. [Action of dydrogesterone in postpubertal menstruation disorders].
    Tabaste JL; Servaud M; Steiner E; Dabir P; Bene B; Pouzet M
    Rev Fr Gynecol Obstet; 1984 Jan; 79(1):19-20, 23-5. PubMed ID: 6531584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dydrogesterone in the treatment of the premenstrual syndrome.
    Kerr GD; Day JB; Munday MR; Brush MG; Watson M; Taylor RW
    Practitioner; 1980 Aug; 224(1346):852-5. PubMed ID: 7001428
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.